시장보고서

상품코드

1625477

백금 기반 항암제 시장 규모, 점유율, 동향, 산업 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)

Platinum-Based Cancer Drugs Market Size, Share, Trends, Industry Analysis Report: By Type, Application, Distribution Channel, and Region - Market Forecast, 2025-2034

발행일: 2024년 12월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 백금 기반 항암제 시장 규모는 2034년까지 27억 3,324만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

난소암, 폐암, 대장암 등 효과적인 화학요법을 필요로 하는 다양한 암의 유병률 증가가 백금계 항암제 시장의 성장을 주도하고 있습니다. 주요 시장 촉진요인으로는 고형암 치료에서 시스플라틴, 카보플라틴, 옥살리플라틴과 같은 백금계 약물의 지속적인 효과, 치료 성적을 향상시키는 병용요법 및 맞춤의료의 발전 등이 있습니다. 암 치료에 대한 접근성이 확대되고 있는 신흥국 시장과 부작용을 줄이고 약물전달을 개선한 새로운 제제 개발에도 비즈니스 기회가 존재합니다.

병용요법의 부상, 독성 감소에 대한 관심, 백금 기반 항암제의 제네릭 의약품의 증가 등 백금 기반 항암제 시장 동향은 예측 기간 동안 전체 시장 확대에 기여할 것으로 보입니다. 백금 제제의 새로운 용도를 찾기 위한 연구가 진행됨에 따라 백금 제제 시장은 지속적으로 성장하여 더 나은 암 치료제에 대한 수요와 저렴한 치료제에 대한 전 세계 수요를 충족시킬 것으로 보입니다.

백금 기반 항암제 시장 보고서 하이라이트

유형별로는 시스플라틴이 난소암, 고환암 등 다양한 암 치료에 오랜 기간 사용되어 효과적이기 때문에 백금 기반 항암제 시장 점유율을 독식하고 있습니다. 그러나 대장암 치료 및 병용요법에 적용이 진행되고 있는 옥살리플라틴 부문이 가장 빠르게 성장하고 있습니다.

난소암은 시스플라틴, 카보플라틴과 같은 백금 제제의 높은 치료 효과로 인해 용도별 시장 점유율이 가장 큰 분야입니다. 폐암은 비소세포폐암의 발병률 증가와 백금 제제와 다른 약물의 병용투여로 인해 가장 빠르게 성장하고 있는 분야입니다.

유통 채널별로는 입원 치료 및 암 치료에서 백금제제를 포함한 화학요법제의 주요 공급처인 병원 내 약국이 시장을 독점하고 있습니다. 온라인 약국은 원격의료와 처방전 보충 및 외래 치료에서 환자의 편의성 향상 추세로 인해 가장 높은 성장세를 보이고 있습니다.

북미가 세계 시장에서 가장 큰 점유율을 차지하고 있으며, 이는 주로 북미의 선진화된 의료 인프라와 높은 암 발병률에 기인합니다. 아시아태평양은 가장 높은 성장률을 보이는 지역으로, 암 발병률 증가, 의료 접근성 향상, 중국 및 인도 등에서의 백금 제제 사용 증가 등이 그 요인으로 작용하고 있습니다.

시장 현황
백금 기반 항암제 시장 역학
- 성장 촉진요인과 기회
  - 백금 기반 항암제의 화학요법 채용 증가
  - 병용요법에 관한 진행중인 조사
- 성장 억제요인과 과제
  - 고비용
PESTEL 분석
백금 기반 항암제 시장 유통 채널 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 백금 기반 항암제 시장 : 유형별

주요 조사 결과
소개
시스플라틴
옥살리플라틴
카보플라틴
기타

제6장 세계의 백금 기반 항암제 시장 : 용도별

주요 조사 결과
소개
대장암
난소암
폐암
기타

제7장 세계의 백금 기반 항암제 시장 : 유통 채널별

주요 조사 결과
소개
병원 병설 약국
소매 약국
온라인 약국

제8장 세계의 백금 기반 항암제 시장 : 지역별

주요 조사 결과
소개
- 백금 기반 항암제 시장 평가 : 지역, 2020-2034년
북미
- 북미 : 유형별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
유럽
- 유럽 : 유형별, 2020-2034
- 유럽 : 용도별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 유형별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 유형별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 유형별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제9장 경쟁 구도

확대와 인수 분석
- 확대
- 인수
제휴/협업/합의/공개

제10장 기업 개요

Bristol-Myers Squibb
Eli Lilly and Company
Sanofi
Pfizer
Novartis
Johnson & Johnson
Teva Pharmaceutical Industries
Hikma Pharmaceuticals
Mylan
AstraZeneca
GlaxoSmithKline
Bayer
Merck & Co.
Amgen
Sun Pharmaceutical Industries

ksm 25.02.06

The global platinum-based cancer drugs market size is expected to reach USD 2,733.24 million by 2034, according to a new study by Polaris Market Research. The report "Platinum-Based Cancer Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (Cisplatin, Oxaliplatin, Carboplatin, and Others), Application, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle, East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of various cancers, such as ovarian, lung, and colorectal cancer, that require effective chemotherapy treatments drives the platinum-based cancer drugs market growth. Key market growth drivers include the continued effectiveness of platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin in treating solid tumors and advancements in combination therapies and personalized medicine that enhance treatment outcomes. Opportunities exist in emerging markets where access to cancer treatments is expanding, as well as in the development of new drug formulations aimed at reducing side effects and improving drug delivery.

A few platinum-based cancer drugs market trends such as the rise of combination therapies, the focus on reducing toxicity, and the growing availability of generic platinum drugs would contribute to the market's overall expansion during the forecast period. As research progresses and new applications for platinum-based drugs are explored, the market is poised for continued growth, addressing both the demand for better cancer treatments and the need for affordable therapies worldwide.

Platinum-Based Cancer Drugs Market Report Highlights

Based on type, the Cisplatin segment dominates the platinum-based cancer drugs market share due to its long-standing use and effectiveness in treating various cancers, including ovarian and testicular cancer. However, the oxaliplatin segment is the fastest-growing, driven by its increasing application in colorectal cancer treatments and combination therapies.

The ovarian cancer segment, by application, holds the largest market share, owing to the high efficacy of platinum-based drugs such as cisplatin and carboplatin in treating this cancer. Lung cancer is the fastest-growing segment, primarily due to the rising incidence of non-small cell lung cancer and the use of platinum-based therapies in combination with other drugs.

By distribution channel, the hospital-based pharmacies segment dominates the market as they are the primary providers of chemotherapy drugs, including platinum-based treatments, for inpatient care and cancer treatments. Online pharmacies are experiencing the highest growth, driven by the increasing trend of remote healthcare and patient convenience for prescription refills and outpatient treatments.

North America holds the largest share of the global market, largely due to advanced healthcare infrastructure and high cancer incidence rates in the region. Asia Pacific is the highest-growing region, fueled by the increasing cancer burden, improving healthcare access, and rising adoption of platinum-based therapies in countries such as China and India.

Polaris Market Research has segmented the platinum-based cancer drugs market report on the basis of type, application, distribution channel, and region:

By Type Outlook (Revenue - USD Million, 2020-2034)

Cisplatin
Oxaliplatin
Carboplatin
Others

By Application Outlook (Revenue - USD Million, 2020-2034)

Colorectal Cancer
Ovarian Cancer
Lung Cancer
Others

By Distribution Channel Outlook (Revenue - USD Million, 2020-2034)

Hospital-Based Pharmacies
Retail Pharmacies
Online Pharmacies

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Platinum-Based Cancer Drugs Market Insights

4.1. Platinum-Based Cancer Drugs Market - Market Snapshot
4.2. Platinum-Based Cancer Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Adoption of Platinum-Based Chemotherapy in Cancer Treatment
  - 4.2.1.2. Ongoing Research in Combination Therapies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Platinum-Based Cancer Drugs Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Platinum-Based Cancer Drugs Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
5.3. Cisplatin
- 5.3.1. Global Platinum-Based Cancer Drugs Market, by Cisplatin, by Region, 2020-2034 (USD Million)
5.4. Oxaliplatin
- 5.4.1. Global Platinum-Based Cancer Drugs Market, by Oxaliplatin, by Region, 2020-2034 (USD Million)
5.5. Carboplatin
- 5.5.1. Global Platinum-Based Cancer Drugs Market, by Carboplatin, by Region, 2020-2034 (USD Million)
5.6. Others
- 5.6.1. Global Platinum-Based Cancer Drugs Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Platinum-Based Cancer Drugs Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
6.3. Colorectal Cancer
- 6.3.1. Global Platinum-Based Cancer Drugs Market, by Colorectal Cancer, by Region, 2020-2034 (USD Million)
6.4. Ovarian Cancer
- 6.4.1. Global Platinum-Based Cancer Drugs Market, by Ovarian Cancer, by Region, 2020-2034 (USD Million)
6.5. Lung Cancer
- 6.5.1. Global Platinum-Based Cancer Drugs Market, by Lung Cancer, by Region, 2020-2034 (USD Million)
6.6. Others
- 6.6.1. Global Platinum-Based Cancer Drugs Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Platinum-Based Cancer Drugs Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
7.3. Hospital-Based Pharmacies
- 7.3.1. Global Platinum-Based Cancer Drugs Market, by Hospital-Based Pharmacies, by Region, 2020-2034 (USD Million)
7.4. Retail Pharmacies
- 7.4.1. Global Platinum-Based Cancer Drugs Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
7.5. Online Pharmacies
- 7.5.1. Global Platinum-Based Cancer Drugs Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)

8. Global Platinum-Based Cancer Drugs Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Platinum-Based Cancer Drugs Market Assessment, By Geography, 2020-2034 (USD Million)
8.3. Platinum-Based Cancer Drugs Market - North America
- 8.3.1. North America: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
- 8.3.2. North America: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
- 8.3.3. North America: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. Platinum-Based Cancer Drugs Market - U.S.
  - 8.3.4.1. U.S.: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.3.4.2. U.S.: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.3.4.3. U.S.: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. Platinum-Based Cancer Drugs Market - Canada
  - 8.3.5.1. Canada: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.3.5.2. Canada: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.3.5.3. Canada: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
8.4. Platinum-Based Cancer Drugs Market - Europe
- 8.4.1. Europe: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
- 8.4.2. Europe: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
- 8.4.3. Europe: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.4. Platinum-Based Cancer Drugs Market - UK
  - 8.4.4.1. UK: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.4.2. UK: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.4.3. UK: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.5. Platinum-Based Cancer Drugs Market - France
  - 8.4.5.1. France: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.5.2. France: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.5.3. France: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.6. Platinum-Based Cancer Drugs Market - Germany
  - 8.4.6.1. Germany: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.6.2. Germany: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.6.3. Germany: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.7. Platinum-Based Cancer Drugs Market - Italy
  - 8.4.7.1. Italy: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.7.2. Italy: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.7.3. Italy: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.8. Platinum-Based Cancer Drugs Market - Spain
  - 8.4.8.1. Spain: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.8.2. Spain: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.8.3. Spain: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.9. Platinum-Based Cancer Drugs Market - Netherlands
  - 8.4.9.1. Netherlands: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.9.2. Netherlands: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.9.3. Netherlands: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.10. Platinum-Based Cancer Drugs Market - Russia
  - 8.4.10.1. Russia: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.10.2. Russia: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.10.3. Russia: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.11. Platinum-Based Cancer Drugs Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.4.11.2. Rest of Europe: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.4.11.3. Rest of Europe: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
8.5. Platinum-Based Cancer Drugs Market - Asia Pacific
- 8.5.1. Asia Pacific: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
- 8.5.2. Asia Pacific: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
- 8.5.3. Asia Pacific: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.4. Platinum-Based Cancer Drugs Market - China
  - 8.5.4.1. China: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.4.2. China: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.4.3. China: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.5. Platinum-Based Cancer Drugs Market - India
  - 8.5.5.1. India: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.5.2. India: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.5.3. India: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.6. Platinum-Based Cancer Drugs Market - Malaysia
  - 8.5.6.1. Malaysia: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.6.2. Malaysia: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.6.3. Malaysia: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.7. Platinum-Based Cancer Drugs Market - Japan
  - 8.5.7.1. Japan: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.7.2. Japan: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.7.3. Japan: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.8. Platinum-Based Cancer Drugs Market - Indonesia
  - 8.5.8.1. Indonesia: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.8.2. Indonesia: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.8.3. Indonesia: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.9. Platinum-Based Cancer Drugs Market - South Korea
  - 8.5.9.1. South Korea: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.9.2. South Korea: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.9.3. South Korea: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.10. Platinum-Based Cancer Drugs Market - Australia
  - 8.5.10.1. Australia: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.10.2. Australia: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.10.3. Australia: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.11. Platinum-Based Cancer Drugs Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.5.11.2. Rest of Asia Pacific: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.5.11.3. Rest of Asia Pacific: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
8.6. Platinum-Based Cancer Drugs Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
- 8.6.2. Middle East & Africa: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
- 8.6.3. Middle East & Africa: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.4. Platinum-Based Cancer Drugs Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.6.4.2. Saudi Arabia: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.6.4.3. Saudi Arabia: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.5. Platinum-Based Cancer Drugs Market - UAE
  - 8.6.5.1. UAE: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.6.5.2. UAE: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.6.5.3. UAE: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.6. Platinum-Based Cancer Drugs Market - Israel
  - 8.6.6.1. Israel: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.6.6.2. Israel: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.6.6.3. Israel: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.7. Platinum-Based Cancer Drugs Market - South Africa
  - 8.6.7.1. South Africa: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.6.7.2. South Africa: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.6.7.3. South Africa: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.8. Platinum-Based Cancer Drugs Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.6.8.2. Rest of Middle East & Africa: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.6.8.3. Rest of Middle East & Africa: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
8.7. Platinum-Based Cancer Drugs Market - Latin America
- 8.7.1. Latin America: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
- 8.7.2. Latin America: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
- 8.7.3. Latin America: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.4. Platinum-Based Cancer Drugs Market - Mexico
  - 8.7.4.1. Mexico: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.7.4.2. Mexico: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.7.4.3. Mexico: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.5. Platinum-Based Cancer Drugs Market - Brazil
  - 8.7.5.1. Brazil: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.7.5.2. Brazil: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.7.5.3. Brazil: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.6. Platinum-Based Cancer Drugs Market - Argentina
  - 8.7.6.1. Argentina: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.7.6.2. Argentina: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.7.6.3. Argentina: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.7. Platinum-Based Cancer Drugs Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Platinum-Based Cancer Drugs Market, by Type, 2020-2034 (USD Million)
  - 8.7.7.2. Rest of Latin America: Platinum-Based Cancer Drugs Market, by Application, 2020-2034 (USD Million)
  - 8.7.7.3. Rest of Latin America: Platinum-Based Cancer Drugs Market, by Distribution Channel, 2020-2034 (USD Million)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Bristol-Myers Squibb
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Eli Lilly and Company
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Sanofi
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Pfizer
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Novartis
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Johnson & Johnson
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Teva Pharmaceutical Industries
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Hikma Pharmaceuticals
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Mylan
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. AstraZeneca
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. GlaxoSmithKline
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. Bayer
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
10.13. Merck & Co.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
10.14. Amgen
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
10.15. Sun Pharmaceutical Industries
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development